The global protein engineering market has been estimated at USD XX billion in 2016 and is projected to reach USD XX by 2021, at a CAGR of about X% during the forecast period from 2016 to 2021. Protein engineering is the design and construction of novel proteins or enzymes with desired properties by manipulation of their genes. The basic approaches of protein engineering are rational design, directed evolution and semi-rational design. Rational design is a computational design which requires amino acid sequence, 3D structure and functional knowledge of protein of interest. Directed evolution imitates the natural process of evolution by reducing the time frame of evolution from millions of years to few months or weeks. A combination of rational design and directed evolution gives a new approach with improved properties and function of enzymes called as semi-rational design.
Request a sample report @ https://www.wiseguyreports.com/sample-request/815367-global-protein-engineering-market-growth-trends-forecasts-2016-2021
Protein engineering finds application in the areas of food and detergent manufacturing, environmental bioremediation, medicine, biopolymer production, nanobiotechnology and industrially important enzyme production.
The global protein engineering market is driven by rising prevalence of protein deficient chronic diseases and the demand for alternatives to chemical processes. However, the market is constrained due to lack of experts to strategize the process and huge costs of the process.
The global protein engineering market can be segmented by end user: biotechnology companies, pharmaceutical companies, academic institutions, and contract research organisations (CRO); by product type: modified proteins, insulin, monoclonal antibodies, modified enzymes, blood factors, tissue plasminogen activator and fusion proteins; and by technology: irrational protein design and rational protein design.
The global protein engineering market has also been geographically segmented into Asia Pacific, Europe, Middle East and North Africa (MENA), North America and Rest of the World, with North America dominating the global market. Asia Pacific is also an emerging market which has a scope for growth and can potentially dominate the market in the future.
The growth of protein engineering market globally is majorly associated to the increasing prevalence of the use of protein engineering in healthcare institutes and hospitals. The major companies dominating this market with its products, services, and continuous product developments are Eli Lilly, Novo Nordisk, Roche, Biogen, Amgen, Fusion Antibodies, Genzyme, and Abbott. However, capitalisation on patents is a major challenge faced by the market players.
Key Deliverables in the Study
Market analysis for the global protein engineering market, with region specific assessments and competition analysis on global and regional scales.
Market definition along with the identification of key drivers and restraints.
Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
Extensively researched competitive landscape section with profiles of major companies along with their market shares.
Identification and analysis of the macro and micro factors that affect the protein engineering market on both global and regional scales.
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
Key points in table of content
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
- Research Methodology
2.2 Analysis Methodology
2.3 Econometric Forecast Model
2.4 Research Assumptions
- Executive Summary
- Key Inferences
- Market Characterisation
5.1 Current Market Scenario
5.2 Market Overview
5.3 Drivers, Restraints, Opportunities, and Challenges (DROC) Analysis
5.3.1 Market Drivers
126.96.36.199 Increasing Prevalence of Protein Deficient Diseases
188.8.131.52 Increased Demand for Alternatives to Chemical Processes
5.3.2 Market Restraints
184.108.40.206 Lack of Experts to Strategize the Process
220.127.116.11 High Costs
5.3.3 Market Challenges
18.104.22.168 Capitalisation on Patents
5.3.4 Market Opportunities
22.214.171.124 Increasing Use of Protein Engineering in Healthcare Institutions and Hospitals
5.4 Neonatal & Prenatal Devices Market Segmentation
5.4.1 By End User
126.96.36.199 Biotechnology Companies
188.8.131.52 Pharmaceutical Companies
184.108.40.206 Academic Institutions
220.127.116.11 Contract Research Organisations (CRO)
5.4.2 By Product Type
18.104.22.168 Modified Proteins
22.214.171.124 Modified Enzymes
126.96.36.199 Monoclonal Antibodies
188.8.131.52 Blood Factors
184.108.40.206 Tissue Plasminogen Activator
220.127.116.11 Fusion Proteins
5.4.3 By Technology
18.104.22.168 Irrational Protein Design
22.214.171.124 Rational Protein Design
5.4.4 By Geography
126.96.36.199 Asia Pacific
188.8.131.52 Middle East & North Africa (MENA)
184.108.40.206 North America
220.127.116.11 Rest of the World
- Industry Analysis
6.1 Key Trends and Developments
6.2 Investment Analysis
6.3 Porter’s Five Forces
6.3.1 Bargaining Power of Suppliers
6.3.2 Bargaining Power of Consumers
6.3.3 Threat of New Entrants
6.3.4 Threat of Substitute Products and Services
6.3.5 Competitive Rivalry within the Industry
- Competitive Landscape
7.1 Key Market Players
7.1.1 Abbott Healthcare
18.104.22.168 Abbott Healthcare- Business Overview
22.214.171.124 Abbott Healthcare- Product and Services Portfolio
126.96.36.199 Abbott Healthcare- Deals Landscape
188.8.131.52 Abbott Healthcare- SWOT Analysis
7.1.2 Eli Lilly
7.1.3 Novo Nordisk
7.1.7 Fusion Antibodies
7.2 Merger and Acquisition Analysis
7.3 New Product Launches
7.4 Agreements, Collaborations & Partnerships
- Analyst Outlook for Investment Opportunities
- Future Outlook of the Market
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)